Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding ...

Potentially lifesaving treatment for rare cancer patients that costs tens of thousands of dollars will be slashed to just $25 ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with the ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will cut ...

Merck MRK is likely to face several headwinds over the next few years that could impact its sales and profits, with the most significant being the upcoming loss of exclusivity for its blockbuster ...

The cancer medication Keytruda is the world’s bestselling drug. But with lower-priced competition set to arrive as soon as 2028, Keytruda’s manufacturer, Merck, is on the brink of losing tens of ...